Genmab A/S

Genmab A/S is a leading biotechnology company that specializes in developing innovative antibody therapeutics for cancer treatment. Established in 1999, the company has a strong focus on research and development, with a pipeline of promising drug candidates in various stages of clinical development. Genmab's flagship product, Darzalex, is a first-in-class antibody therapy for multiple myeloma, approved in over 90 countries worldwide. The company's DuoBody technology platform enables the creation of bispecific antibodies that can target multiple disease targets simultaneously, offering a potential breakthrough in cancer treatment. With a global presence and a team of over 600 employees, Genmab is dedicated to improving the lives of cancer patients through the development of innovative and effective therapies.